Domača stranBSLN • SWX
add
Basilea Pharmaceutica AG Allschwil
Prejšnji trg. dan.
41,15 CHF
Dnevni razpon
40,60 CHF - 41,45 CHF
Letni razpon
32,00 CHF - 49,00 CHF
Tržna kapitalizacija
540,62 mio. CHF
Povprečni obseg
17,18 tis.
Razm. P/E
47,10
Dividendna donosnost
-
Primarna borza
SWX
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (CHF) | dec. 2023info | Sprememba L/L |
|---|---|---|
Prihodek | 36,36 mio. | −19,30 % |
Stroški poslovanja | 7,96 mio. | 12,34 % |
Čisti dohodek | −10,69 mio. | −187,82 % |
Čista dobičkovnost prihodkov | −29,41 | −208,81 % |
Earnings per share | — | — |
EBITDA | −7,88 mio. | −152,08 % |
Efektivna davčna stopnja | 0,08 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (CHF) | dec. 2023info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 59,93 mio. | −29,21 % |
Skupna sredstva | 173,29 mio. | −21,53 % |
Skupne obveznosti | 183,29 mio. | −24,12 % |
Celoten lastniški kapital | −10,00 mio. | — |
Shares outstanding | 12,00 mio. | — |
Razmerje P/B | −49,58 | — |
Donosnost sredstev | −11,81 % | — |
Donosnost kapitala | −17,26 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (CHF) | dec. 2023info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −10,69 mio. | −187,82 % |
Denar iz dejavnosti | −3,81 mio. | −210,31 % |
Denar iz naložb | −322,50 tis. | −100,69 % |
Denar iz financiranja | −20,11 mio. | −4,52 % |
Neto sprememba denarnih sredstev | −24,31 mio. | −178,80 % |
Prost denarni tok | −4,62 mio. | −154,24 % |
Vizitka
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
Generalni direktor
Datum ustanovitve
okt. 2000
Spletno mesto
Zaposleni
147
